المؤلفون: Fernando Nolasco, Luísa Semedo, Francisco Ribeiro, Joaquim Calado, Maria Do Mar Menezes, Inês Aires

المصدر: Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP

مصطلحات موضوعية: medicine.medical_specialty, Thrombotic microangiopathy, medicine.medical_treatment, Immunosuppressive Agents / adverse effects, Thrombotic Microangiopathies / immunology, urologic and male genital diseases, Gastroenterology, HSM PNEU, Tacrolimus, Immunocompromised Host, Internal medicine, Tacrolimus / adverse effects, medicine, Lung transplantation, Humans, Everolimus, Immunosuppressive Agents / administration & dosage, Lung Transplantation* / adverse effects, Immunosuppression Therapy, Transplantation, Leukopenia, Everolimus / therapeutic use, Kidney Diseases / immunology, medicine.diagnostic_test, Thrombotic Microangiopathies, business.industry, Immunosuppression, HCC NEF, Microangiopathic hemolytic anemia, Mycophenolic Acid, Middle Aged, medicine.disease, Mycophenolic Acid / therapeutic use, Immunosuppression / adverse effects, Kidney Diseases, Surgery, Female, Renal biopsy, medicine.symptom, business, Immunosuppressive Agents, Lung Transplantation, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea946c997df5325ed33bb82f032a71caTest

المؤلفون: Henk M.W. Verheul, Tanja D. de Gruijl, Marco B. Polee, Paul Hamberg, Charlotte M. Huijts, Maartje Los, Inge M. Werter, Sinéad. M. Lougheed, Hans van Vliet, John B. A. G. Haanen, Helgi H. Helgason, Metin Tascilar

المساهمون: Internal medicine, Medical oncology, CCA - Cancer biology and immunology, AII - Cancer immunology, Medical oncology laboratory, Academic Medical Center

المصدر: Werter, I M, Huijts, C M, Lougheed, S M, Hamberg, P, Polee, M B, Tascilar, M, Los, M, Haanen, J B A G, Helgason, H H, Verheul, H M, de Gruijl, T D, van der Vliet, H J & Dutch WIN-O Consortium 2019, ' Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus ', Cancer Immunology, Immunotherapy, vol. 68, no. 5, pp. 787-798 . https://doi.org/10.1007/s00262-019-02313-zTest
Cancer Immunology, Immunotherapy, 68(5), 787-798. Springer Science and Business Media Deutschland GmbH
Cancer Immunology Immunotherapy, 68, 5, pp. 787-798
Cancer immunology, immunotherapy, 68(5), 787-798. Springer Science and Business Media Deutschland GmbH
Cancer Immunology Immunotherapy, 68, 787-798

مصطلحات موضوعية: Oncology, Male, Cancer Research, Renal Cell/drug therapy, Everolimus/therapeutic use, T-Lymphocytes, Phases of clinical research, TOR Serine-Threonine Kinases/metabolism, T-Lymphocytes, Regulatory, Tyrosine-kinase inhibitor, chemistry.chemical_compound, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 0302 clinical medicine, Immunology and Allergy, Medicine, TOR Serine-Threonine Kinases, Middle Aged, Kidney Neoplasms, Vascular endothelial growth factor, Kidney Neoplasms/drug therapy, Treatment Outcome, Cyclophosphamide/therapeutic use, Female, Immunosuppressive Agents, medicine.drug, medicine.medical_specialty, Cyclophosphamide, medicine.drug_class, Immunology, T-Lymphocytes, Regulatory/immunology, 03 medical and health sciences, Immune system, Internal medicine, Humans, Everolimus, Carcinoma, Renal Cell, PI3K/AKT/mTOR pathway, Aged, Cell Proliferation, business.industry, Carcinoma, Interim analysis, Survival Analysis, chemistry, Carcinoma, Renal Cell/drug therapy, Immunosuppressive Agents/therapeutic use, Regulatory/immunology, business, 030215 immunology, Follow-Up Studies

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2b177ecb737553601b0a3e3e00e7159Test
https://pubmed.ncbi.nlm.nih.gov/30756132Test